These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 16270092)

  • 1. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study.
    Chang SC; Lacey JV; Brinton LA; Hartge P; Adams K; Mouw T; Carroll L; Hollenbeck A; Schatzkin A; Leitzmann MF
    Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):723-30. PubMed ID: 17416763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis.
    Crosbie EJ; Zwahlen M; Kitchener HC; Egger M; Renehan AG
    Cancer Epidemiol Biomarkers Prev; 2010 Dec; 19(12):3119-30. PubMed ID: 21030602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype.
    McCullough ML; Patel AV; Patel R; Rodriguez C; Feigelson HS; Bandera EV; Gansler T; Thun MJ; Calle EE
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):73-9. PubMed ID: 18187388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for the incidence of endometrial cancer according to the aggressiveness of disease.
    Weiss JM; Saltzman BS; Doherty JA; Voigt LF; Chen C; Beresford SA; Hill DA; Weiss NS
    Am J Epidemiol; 2006 Jul; 164(1):56-62. PubMed ID: 16675538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What influence does hormone replacement therapy have on endometrial cancer risk?
    Barakat RR
    Nat Clin Pract Oncol; 2005 Nov; 2(11):546-7. PubMed ID: 16270092
    [No Abstract]   [Full Text] [Related]  

  • 6. Hormonal carcinogenesis and socio-biological development factors in endometrial cancer: a clinical review.
    Tinelli A; Vergara D; Martignago R; Leo G; Malvasi A; Tinelli R
    Acta Obstet Gynecol Scand; 2008; 87(11):1101-13. PubMed ID: 18607816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of breast, endometrial and ovarian cancer in users of hormonal preparations.
    Bernstein L
    Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):288-96. PubMed ID: 16611204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hormone replacement therapy after endometrial or ovarian cancer].
    Daraï E; Gompel A; Deval B; Laplace C; Lemoine A; Labeyrie E; Neu AM; Poitout P
    Gynecol Obstet Fertil; 2000 Mar; 28(3):198-204. PubMed ID: 10786400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone replacement therapy and the endometrium.
    Daayana S; Holland CM
    Menopause Int; 2009 Sep; 15(3):134-8. PubMed ID: 19723685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progestogen deficiency and endometrial cancer risk.
    Schindler AE
    Maturitas; 2009 Apr; 62(4):334-7. PubMed ID: 19231117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone replacement therapy after treatment of endometrial cancer.
    Tangjitgamol S; Manusirivithaya S; Hanprasertpong J; Kavanagh JJ
    Gynecol Obstet Invest; 2008; 65(1):35-8. PubMed ID: 17687189
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.